Question 1

Am I eligible for this trial based on my cancer type and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC clinical trial (NCT07098988). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential benefits and risks of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC clinical trial (NCT07098988). Contact the study team or your healthcare provider for specific answers.

Question 3

How does this treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC clinical trial (NCT07098988). Contact the study team or your healthcare provider for specific answers.

Question 4

What will the treatment schedule look like, and how often will I need to visit the clinic?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC clinical trial (NCT07098988). Contact the study team or your healthcare provider for specific answers.

Question 5

What kind of monitoring will be done during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC clinical trial (NCT07098988). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any costs involved or is it covered by insurance?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC clinical trial (NCT07098988). Contact the study team or your healthcare provider for specific answers.

What this study is about